Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Gadolinium‐based chelates are a mainstay of contrast agents for magnetic resonance
imaging (MRI) in the clinic. However, their toxicity elicits severe side effects and the Food …

Rational structure design benefits the development of efficient nanoplatforms for tumor
theranostic application. In this work, a multifunctional polydopamine (PDA)-coated …

The Alzheimer center of the VU University Medical Center opened in 2000 and was initiated
to combine both patient care and research. Together, to date, all patients forming the …

In this article, the authors aim to maximally utilize multimodality neuroimaging and genetic
data for identifying Alzheimer's disease (AD) and its prodromal status, Mild Cognitive …

With the advancement in magnetic resonance imaging (MRI) technology, traditional single T
1 or T 2 contrast agents struggle to meet the demend for accuracy imaging. In comparison …

Dementia with Lewy bodies (DLB) is clinically defined by the presence of visual
hallucinations, fluctuations, rapid eye movement (REM) sleep behavioral disorder, and …

Diagnosis of neurological diseases is a growing concern and one of the most difficult
challenges for modern medicine. According to the World Health Organisation's recent report …

Background and Purpose—Cerebral small vessel disease is characterized by a wide range
of focal and global brain changes. We used a magnetic resonance imaging segmentation …